Basel’s bitter pill – Aaron Woolner column

Basel’s bitter pill

aaron-woolner

People don’t like taking medicine – it doesn’t matter whether a child’s polio drop is disguised on a sugar cube, or if they are given a treat afterwards, the trudge to the medical centre isn’t a happy one. But when the treatment turns out to be a nostrum the pain is even greater.

And there are certain parts of Basel III that are pure quackery for Asian banks, a prime example being the counter-cyclical capital buffer, which in the context of a region well-equipped in microeconomic regulatory

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

If you already have an account, please sign in here.

Register

Want to know what’s included in our free membership? Click here

This address will be used to create your account

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: